Archive | Latest Research

CBT Pharmaceuticals’ PD-L1 Antibody Shows Promising Anti-Tumor Activity in Preclinical Studies

CBT Pharmaceuticals‘ anti-PD-L1 antibody CBT-502 has shown promising immune activation and inhibition of tumor growth in preclinical models of cancer, according to new preclinical data.

Read the full story

Posted in Melanoma In The News, Other Melanoma Research

Circulating tumor cells associated with relapse in late-stage melanoma patients

A study revealing a connection between circulating tumor cells (CTCs) and relapse in stage IV melanoma patients points to liquid biopsy as a potential predictor of patients at high risk for disease progression.

Read the full story

Posted in Melanoma In The News, Other Melanoma Research

Cancer immunotherapy uses melanin against melanoma

Researchers have developed a melanin-enhanced cancer immunotherapy technique that can also serve as a vaccine, based on early experiments done in a mouse model.

Read the full story

Posted in Melanoma In The News, Other Melanoma Research

Scientists Unravel Novel Mechanism by Which Tumours Evade Cancer Immunotherapies

New York, NY (Scicasts) – A Ludwig Cancer Research study led by Benoit Van den Eynde, Director of Ludwig Brussels, has identified a novel mechanism by which tumours of the aggressive skin cancer melanoma can resist cancer immunotherapy.

Read the full story

Posted in Melanoma In The News, Other Melanoma Research

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories